We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+67.45%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.21B
AUM Growth
+$315M
Cap. Flow
-$130M
Cap. Flow %
-5.88%
Top 10 Hldgs %
38.34%
Holding
95
New
23
Increased
27
Reduced
21
Closed
14

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$74.6M
2
ABVX
Abivax
ABVX
+$61.3M
3
BDX icon
Becton Dickinson
BDX
+$55.7M
4
DXCM icon
DexCom
DXCM
+$51.4M
5
RGEN icon
Repligen
RGEN
+$48.6M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$108M
2
CYTK icon
Cytokinetics
CYTK
+$92.7M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$84M
4
QURE icon
uniQure
QURE
+$63.1M
5
KALV
KalVista Pharmaceuticals
KALV
+$54.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRON icon
26
Disc Medicine
IRON
$2.97B
$33M 1.49%
500,000
+360,000
+257% +$21.4M
NRIX icon
27
Nurix Therapeutics
NRIX
$2.62B
$32.1M 1.45%
3,475,000
+1,475,000
+74% +$15.3M
CRNX icon
28
Crinetics Pharmaceuticals
CRNX
$8.9B
$31.2M 1.41%
750,000
-750,000
-50% -$24M
CLDX icon
29
Celldex Therapeutics
CLDX
$3.26B
$31.2M 1.41%
1,205,000
-545,000
-31% -$12.6M
ZYME icon
30
Zymeworks
ZYME
$1.7B
$30.1M 1.36%
1,765,000
+615,000
+53% +$8.8M
DHR icon
31
Danaher
DHR
$141B
$29.7M 1.34%
150,000
+100,000
+200% +$19.9M
RVMD icon
32
Revolution Medicines
RVMD
$42.1B
$29.4M 1.33%
630,000
-570,000
-48% -$22.3M
RAPP
33
Rapport Therapeutics
RAPP
$2.22B
$28.2M 1.27%
+950,000
New +$16.9M
ELVN icon
34
Enliven Therapeutics
ELVN
$4.31B
$23.7M 1.07%
1,160,000
+910,000
+364% +$18.3M
GERN icon
35
Geron
GERN
$1.01B
$23.6M 1.07%
17,225,000
-6,550,000
-28% -$8.72M
BLTE
36
Belite Bio
BLTE
$6.44B
$23.1M 1.04%
+312,500
New +$20.5M
RARE icon
37
Ultragenyx Pharmaceutical
RARE
$2.54B
$22.6M 1.02%
+750,000
New +$22.5M
VERA icon
38
Vera Therapeutics
VERA
$2.3B
$22.1M 1%
760,000
-2,340,000
-75% -$54.1M
LXEO icon
39
Lexeo Therapeutics
LXEO
$357M
$21.6M 0.97%
3,250,000
+21,839
+0.7% +$106K
BDTX icon
40
Black Diamond Therapeutics
BDTX
$110M
$21M 0.95%
5,550,000
-50,000
-0.9% -$146K
DAWN
41
DELISTED
Day One Biopharmaceuticals
DAWN
$18.9M 0.85%
2,675,000
-325,000
-11% -$2.24M
SLDB icon
42
Solid Biosciences
SLDB
$857M
$18.4M 0.83%
2,975,000
+1,470,000
+98% +$8.6M
AXSM icon
43
Axsome Therapeutics
AXSM
$10.8B
$18.2M 0.82%
+150,000
New +$16.9M
TSHA icon
44
Taysha Gene Therapies
TSHA
$1.82B
$18M 0.81%
5,500,000
+2,500,000
+83% +$7.08M
APGE icon
45
Apogee Therapeutics
APGE
$10.2B
$16.9M 0.76%
+425,000
New +$16.2M
SVRA icon
46
Savara
SVRA
$1.19B
$14.3M 0.65%
4,015,000
-7,000,000
-64% -$20.7M
BRKR icon
47
Bruker
BRKR
$7.8B
$14.3M 0.65%
440,000
-60,000
-12% -$2.14M
REGN icon
48
Regeneron Pharmaceuticals
REGN
$79.5B
$14.1M 0.63%
+25,000
New +$14.1M
QURE icon
49
uniQure
QURE
$3.15B
$13.1M 0.59%
225,000
-3,475,000
-94% -$63.1M
BBNX
50
Beta Bionics
BBNX
$635M
$11.9M 0.54%
600,000
+50,000
+9% +$879K
1
2
3 4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Vestal Point Capital held 95 positions worth $2.21B, up 17% from $1.9B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Vestal Point Capital withdrew a net $130M in Q3 2025, closing 14 positions and reducing 21 holdings. Its most notable exit was GE HealthCare, an estimated $51.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Vestal Point Capital opened a new position in Abivax worth $84.9M.

  • Vestal Point Capital's largest Q3 2025 buy was Abivax: 1,000,000 shares worth $84.9M.
  • Vestal Point Capital added most to Ascendis Pharma A/S in Q3 2025, an estimated $74.6M increase.
  • Vestal Point Capital's biggest Q3 2025 reduction was Arcellx, cutting an estimated $108M.
  • Vestal Point Capital fully exited GE HealthCare in Q3 2025, selling an estimated $51.8M.
  • Vestal Point Capital's ten largest holdings make up 38% of its $2.21B portfolio in Q3 2025.
  • Vestal Point Capital opened 23 new positions and closed 14 in Q3 2025.
  • Vestal Point Capital's portfolio value rose 17% quarter-over-quarter to $2.21B.

Based on Vestal Point Capital's 13F filing for Q3 2025, filed 14 Nov 2025.